LHRH antagonist cetrorelix reduces prostate size and gene expression of proinflammatory cytokines and growth factors in a rat model of benign prostatic hyperplasia

Prostate

Volumn 71, Issue 7, 2011, Pages 736-747

  Rick, Ferenc G ^a,b   Schally, Andrew V ^a,b   Block, Norman L ^a,b   Halmos, Gabor ^a,b,c   Perez, Roberto ^a,b   Fernandez, Jesus B ^a,b   Vidaurre, Irving ^a   Szalontay, Luca ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Benign prostatic hyperplasia; Growth factors; LHRH; Proinflammatory cytokines; Rats

Indexed keywords

BONE MORPHOGENETIC PROTEIN 5; CANCER GROWTH FACTOR; CETRORELIX; CXCL2 CHEMOKINE; FIBROBLAST GROWTH FACTOR 14; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR 8; GAMMA INTERFERON; GONADORELIN RECEPTOR; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; KERATINOCYTE GROWTH FACTOR; LYMPHOTOXIN ALPHA BETA; MESSENGER RNA; OSTEOGENIC PROTEIN 1; PROSTATE SPECIFIC ANTIGEN; SOMATOMEDIN B; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TUMOR GROWTH FACTOR BETA 1; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN C;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; GENE EXPRESSION; MALE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; CYTOKINES; DISEASE MODELS, ANIMAL; GENE EXPRESSION; GONADOTROPIN-RELEASING HORMONE; HORMONE ANTAGONISTS; MALE; PROSTATE; PROSTATIC HYPERPLASIA; RATS; RATS, WISTAR; RECEPTORS, LHRH; RNA, MESSENGER; TESTOSTERONE;

EID: 79952774082     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21289     Document Type: Article

References (47)

1. Roehrborn CG, Siami P, Barkin J, Damiao R, Becher E, Minana B, Mirone V, Castro R, Wilson T, Montorsi F, CombAT Study Group. The influence of baseline parameters on changes ininternational prostatesymptomscore with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study. Eur Urol 2009; 55:461-471.
2. Parsons JK, Kashefi C. Physical activity, benign prostatic hyperplasia, and lower urinary tract symptoms. Eur Urol 2008; 53:1228-1235.
3. Briganti A, Capitanio U, Suardi N, Gallina A, Salonia A, Bianchi M, Tutolo M, Di Girolamo V, Guazzoni G, Rigatti P, Montorsi F. Benign prostatic hyperplasia and its aetiologies. Eur Urol Suppl 2009;8:865-871.
4. Kramer G, Mitteregger D, Marberger M. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? Eur Urol 2007;51:1202-1216.
5. Di Silverio F, Gentile V, De Matteis A, Mariotti G, Giuseppe V, Luigi PA, Sciarra A. Distribution ofinflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: Aretrospective analysis. Eur Urol 2003;43: 164-175. (Pubitemid 36221971)
6. Nickel JC, Roehrborn CG, O'leary MP, Bostwick DG, Somerville MC, Rittmaster RS. Examination of the relationship between symptoms of prostatitis and histological inflammation: Baseline data from the REDUCE chemoprevention trial. J Urol 2007; 178:896-900, discussion 900-901.
7. St Sauver JL, Jacobson DJ, Girman CJ, Lieber MM, McGree ME, Jacobsen SJ. Tracking of longitudinal changes in measures of benign prostatic hyperplasia in a population based cohort. JUrol 2006;175(3 Pt 1):1018-1022, discussion 1022.
8. Kessler OJ, Keisari Y, Servadio C, Abramovici A. Role of chronic inflammation in the promotion of prostatic hyperplasia in rats. J Urol 1998;159:1049-1053. (Pubitemid 28106592)
9. Lee KL, Peehl Donna M. Molecular and cellular pathogenesis of benign prostatic hyperplasia. J Urol 2004;172:1784-1791. (Pubitemid 39363056)
10. Untergasser G, Madersbacher S, Berger P. Benign prostatic hyperplasia: Age-related tissue-remodeling. Exp Gerontol 2005;40:121-128. (Pubitemid 40343002)
11. Kohnen PW, Drach GW. Patterns of inflammation in prostatic hyperplasia: A histologic and bacteriologic study. J Urol 1979;121(6):755-760. (Pubitemid 9205780)
12. Theyer G, Kramer G, Assmann I, Sherwood E, Preinfalk W, Marberger M, Zechner O, Steiner GE. Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia. Lab Invest 1992;66:96-107.
13. Kramer G, Steiner GE, Handisurya A, Stix U, Haitel A, Knerer B, Gessl A, Lee C, Marberger M. Increased expression of lymphocyte-derived cytokines in benign hyperplastic prostate tissue, identification of the producing cell types, and effect of differentially expressed cytokines on stromal cell proliferation. Prostate 2002;52:43-58. (Pubitemid 34553191)
14. Djavan B, Eckersberger E, Espinosa G, Kramer G, Handisurya A, Lee C, Marberger M, Lepor H, Steiner GE. Complex mechanisms in prostatic inflammatory response. Eur Urol Suppl 2009;8:872-878.
15. Lucia MS, Lambert JR. Growth factors in benign prostatic hyperplasia: Basic science implications. Curr Urol Rep 2008;9:272-278.
16. Nickel JC, Roehrborn CG, O'Leary MP, Bostwick DG, Somerville MC, Rittmaster RS. The relationship between prostate inflammation and lower urinary tract symptoms: Examination of baseline data from the REDUCE trial. Eur Urol 2008;54:1379-1384.
17. Steiner GE, Newman ME, Paikl D, Stix U, Memaran-Dagda N, Lee C, Marberger MJ. Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate. Prostate 2003;56:171-182. (Pubitemid 36918167)
18. Handisurya A, Steiner GE, Stix U, Ecker RC, Pfaffeneder-Mantai S, Langer D, Kramer G, Memaran-Dadgar N, Marberger M. Differential expression of interleukin-15, a pro-inflammatory cytokine and T-cell growth factor, and its receptor in human prostate. Prostate 2001;49:251-262. (Pubitemid 33117000)
19. Steiner GE, Stix U, Handisurya A, Willheim M, Haitel A, Reithmayr F, Paikl D, Ecker RC, Hrachowitz K, Kramer G, Lee C, Marberger M. Cytokine expression pattern in benign prostatic hyperplasia infiltrating T cells and impact of lymphocytic infiltration on cytokine mRNA profile in prostatic tissue. Lab Invest 2003;83:1131-1146. (Pubitemid 37013048)
20. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Hittmair A, Zhang J, Thurnher M, Bartsch G, Klocker H. Regulation of prostatic growth and function by peptide growth factors. Prostate 1996;28:392-405. (Pubitemid 26187724)
21. Schally AV. New approaches to the therapy of various tumors based on peptide analogues. Horm Metab Res 2008;40:315-322. (Pubitemid 351859442)
22. Gonzalez-Barcena D, Vadillo-Buenfil M, Gomez-Orta F, Fuentes Garcia M, Cardenas-Cornejo I, Graef-Sanchez A, Comaru-Schally AM, Schally AV. Responses to the antagonistic analog of LH-RH(SB-75, Cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancer. Prostate 1994;24:84-92. (Pubitemid 24073107)
23. Comaru-Schally AM, Brannan W, Schally AV, Colcolough M, Monga M. Efficacy and safety of luteinizing hormone-releasing hormone antagonist cetrorelix in the treatment of symptomatic benign prostatic hyperplasia. J Clin Endocrinol Metab 1998;83:3826-3831. (Pubitemid 28513557)
24. Debruyne F, Gres AA, Arustamov DL. Placebo-controlled dose-ranging phase 2 study of subcutaneously administered LHRH antagonist cetrorelix in patients with symptomatic benign prostatic hyperplasia. Eur Urol 2008;54:170-177.
25. McConnell JD. Benign prostatic hyperplasia. Hormonal treatment. Urol Clin North Am 1995;22:387-400.
26. Wemyss-Holden SA, Hamdy FC, Hastie KJ. Streoid abuse in athletes, prostatic enlargement and bladder outflow obstruction- Is there a relationship? Br J Urol 1994;74:476-478.
27. Maggi CA, Manzini S, Giuliani S, Meli A. Infravesical outflow obstruction in rats:Acomparison of two models. Gen Pharmacol 1989;20(3):345-349. (Pubitemid 19093440)
28. Constantinou CE. Influence of hormone treatment on prostate growth and micturition characteristics of the rat. Prostate 1996;29:30-35. (Pubitemid 26250367)
29. Liu HP, Chen GL, Liu P, Xu XP. Amlodipine alone or combined with terazosin improves lower urinary tract disorder in rat models of benign prostatic hyperplasia or detrusor instability: Focus on detrusor overactivity. BJU Int 2009;104:1752-1757.
30. Pandita RK, Persson K, Hedlund P, Andersson KE. Testosterone-induced prostatic growth in the rat causes bladder overactivity unrelated to detrusor hypertrophy. Prostate 1998;35:102-108. (Pubitemid 28183292)
31. Scolnik MD, Servadio C, Abramovici A. Comparative study of experimentally induced benign and atypical hyperplasia in the ventral prostate of different rat strains. J Androl 1994;15:287-297. (Pubitemid 24256641)
32. Kojima Y, Sasaki S, Oda N, Koshimizu TA, Hayashi Y, Kiniwa M, Tsujimoto G, Kohri K. Prostate growth inhibition by subtype-selective alpha(1)- adrenoceptor antagonist naftopidil in benign prostatic hyperplasia. Prostate 2009;69:1521-1528.
33. Bajusz S, Csernus VJ, Janaky T, Bokser L, Fekete M, Schally AV. New antagonists of LHRH. II. Inhibition and potentiation of LHRH by closely related analogues. Int J Pept Protein Res 1988;32:425-435. (Pubitemid 19042048)
34. Horvath JE, Toller GL, Schally AV, Bajo AM, Groot K. Effect of long-term treatment with low doses of the LHRH antagonist Cetrorelix on pituitary receptors for LHRH and gonadal axis in male and female rats. Proc Natl Acad Sci USA 2004;101:4996-5001. (Pubitemid 38469191)
35. Nemeth JA, Lee C. Prostatic ductal system in rats: Regional variation in stromal organization. Prostate 1996;28:124-128. (Pubitemid 26066251)
36. Heinrich E, Schally AV, Buchholz S, Rick FG, Halmos G, Mile M, Groot K, Hohla F, Zarandi M, Varga JL. Dose-dependent growth inhibition in vivo of PC-3 prostate cancer with a reduction in tumoral growth factors after therapy with GHRH antagonist MZ-J-7-138. Prostate 2008;68:1763-1772.
37. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001;29:e45.
38. Bellyei S, Schally AV, Zarandi M, Varga JL, Vidaurre I, Pozsgai E. GHRH antagonists reduce the invasive and metastatic potential of human cancer cell lines in vitro. Cancer Lett 2010;293:31-40.
39. Halmos G, Arencibia JM, Schally AV, Davis R, Bostwick DG. High incidence of receptors for luteinizing hormone-releasing hormone (LHRH) and LHRH receptor gene expression in human prostate cancer. J Urol 2000;163:623-629. (Pubitemid 30060537)
40. Emons G, Gründker C, Günthert AR, Westphalen S, Kavanagh J, Verschraegen C. GnRH antagonists in the treatment of gynecological and breast cancers. Endocr Relat Cancer 2003;10:291-299. (Pubitemid 36758655)
41. Siejka A, Schally AV, Block NL, Barabutis N. Mechanisms of inhibition of human benign prostatic hyperplasia in vitro by LHRH antagonist Cetrorelix. BJU Int 2010; DOI:10.1111/j.1464-410X.2010.09215.x.
42. Nickel JC, Downey J, Young I, Boag S. Asymptomatic inflammation and/or infection in benign prostatic hyperplasia. BJU Int 1999;84:976-981.
43. Tagaya M, Oka M, Ueda M, Takagaki K, Tanaka M, Ohgi T, Yano J. Eviprostat suppresses proinflammatory gene expression in the prostate of rats with partial bladder-outlet obstruction: A genome-wide DNA microarray analysis. Cytokine 2009;47:185-193.
44. Konig JE, Senge T, Allhoff EP, Konig W. Analysis of the inflammatory network in benign prostate hyperplasia and prostate cancer. Prostate 2004;58:121-129. (Pubitemid 38160899)
45. Giri D, Ittmann M. Interleukin-1alpha is a paracrine inducer of FGF7, a key epithelial growth factor in benign prostatic hyperplasia. Am J Pathol 2000;157:249-255. (Pubitemid 30641741)
46. Martinez-Moczygemba M, Huston DP. Biology of common beta receptor-signaling cytokines: IL-3, IL-5, and GM-CSF. J Allergy Clin Immunol 2003;112:653-665.
47. Förster R, Mattis AE, Kremmer E, Wolf E, Brem G, Lipp M. A putative chemokine receptor, BLR1, directs B cell migration to defined lymphoid organs and specific anatomic compartments of the spleen. Cell 1996;87:1037-1047. (Pubitemid 26427987)